EUVIMEDEUVIMED entdecken
Crossref

Profiling adverse reactions to novel drug-resistant tuberculosis regimens containing bedaquiline and linezolid

Ramakant Dixit, Prakhar Maheshwari, Ankur Gupta

Annals of the National Academy of Medical Sciences (India) · 18.06.2026 · 62 · 268-277

DOI: 10.25259/anams_257_2025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the National Academy of Medical Sciences (India), online erschienen am 18.06.2026. Verfasst von Ramakant Dixit und 2 weiteren Autor:innen. Die Arbeit nennt 51 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Tuberculosis (TB) poses a major global health concern, with drug-resistant strains posing significant treatment challenges. Drug-resistant TB (DR-TB) requires second-line anti-TB drugs, which often have severe side effects. This study focuses on evaluating adverse drug reactions (ADRs) in DR-TB patients to improve treatment outcomes by timely identification and management. Material and Methods This was a 2-year prospective observational descriptive study of 145 registered DR-TB patients initiated on treatment, among whom 79 developed ADRs. Demographic, clinical, and treatment data were collected from all 79 DR-TB patients. ADRs were assessed using statistical methods to determine any associations with factors such as age, sex, HIV status, and treatment regimen.

Results

The mean age of the study population having ADR was 38.5 years, with 67.0% male. Most patients (78.4%) were underweight, 77.2% were anemic, and 29.1% had comorbidities, mainly hypertension. About 74.6% of patients had a previous history of anti-TB treatment. Rifampicin (R)-mono resistance (64.5%) was the predominant resistance pattern. The overall ADR incidence was 54.5%, with peripheral neuropathy being the most frequent ADR (41.3%). Linezolid was the most commonly implicated drug, responsible for 58.6% of ADRs.

Conclusion

The study found a high incidence (54.5%) of ADRs in DR-TB patients, particularly peripheral neuropathy and anemia linked to linezolid. There were no significant associations between ADR occurrence and factors like age, sex, or HIV status. Vigilant monitoring and early intervention are critical for managing ADRs and improving treatment adherence among these patients.

Zitieren

APA

Dixit, R., Maheshwari, P., & Gupta, A. (2026). Profiling adverse reactions to novel drug-resistant tuberculosis regimens containing bedaquiline and linezolid. Annals of the National Academy of Medical Sciences (India), 62, 268-277. https://doi.org/10.25259/anams_257_2025

Vancouver

Dixit R, Maheshwari P, Gupta A. Profiling adverse reactions to novel drug-resistant tuberculosis regimens containing bedaquiline and linezolid. Annals of the National Academy of Medical Sciences (India). 2026;62:268-277. doi:10.25259/anams_257_2025

BibTeX
@article{Dixit2026,
  author = {Dixit, Ramakant and Maheshwari, Prakhar and Gupta, Ankur},
  title = {Profiling adverse reactions to novel drug-resistant tuberculosis regimens containing bedaquiline and linezolid},
  journal = {Annals of the National Academy of Medical Sciences (India)},
  year = {2026},
  volume = {62},
  pages = {268--277},
  doi = {10.25259/anams_257_2025}
}
Kostenlos starten →